Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Accured Expenses (2020 - 2026)

Entrada Therapeutics has reported Change in Accured Expenses over the past 4 years, most recently at $2.2 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 605.88% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $4.7 million, up 177.63%, while the annual FY2025 figure was $4.7 million, 177.63% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $2.2 million at Entrada Therapeutics, down from $3.7 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $6.9 million in Q3 2022 and troughed at -$5.5 million in Q1 2025.
  • A 4-year average of $751500.0 and a median of $1.8 million in 2023 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: crashed 795.59% in 2023 and later skyrocketed 605.88% in 2025.
  • Year by year, Change in Accured Expenses stood at -$4.3 million in 2022, then surged by 145.03% to $2.0 million in 2023, then tumbled by 121.74% to -$425000.0 in 2024, then skyrocketed by 605.88% to $2.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for TRDA at $2.2 million in Q4 2025, $3.7 million in Q3 2025, and $4.3 million in Q2 2025.